ERR4976601
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
- overall_survival_months
- 96
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.380
- ANGIOGENESIS+0.370
- HEDGEHOG_SIGNALING+0.350
- PANCREAS_BETA_CELLS+0.310
- TGF_BETA_SIGNALING+0.310
- APICAL_SURFACE+0.290
- APOPTOSIS+0.260
- APICAL_JUNCTION+0.240
- COAGULATION+0.240
- HYPOXIA+0.240
Top 10 suppressed
- MYC_TARGETS_V2-0.380
- E2F_TARGETS-0.300
- G2M_CHECKPOINT-0.300
- DNA_REPAIR-0.290
- INTERFERON_ALPHA_RESPONSE-0.290
- INTERFERON_GAMMA_RESPONSE-0.200
- CHOLESTEROL_HOMEOSTASIS-0.180
- MYC_TARGETS_V1-0.180
- UNFOLDED_PROTEIN_RESPONSE-0.140
- BILE_ACID_METABOLISM-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 22620634-aa34-4cb5-a37f-5a7b0c47cd0e | — | — | 0.894 |
| 2 | TCGA-E9-A1NH-01A-11R-A14D-07 | — | A | 0.872 |
| 3 | 4c7083b3-eccc-4d80-a31d-6fd3cd0222b4 | — | — | 0.854 |
| 4 | TCGA-E2-A153-01A-12R-A12D-07 | — | A | 0.845 |
| 5 | TCGA-BH-A0AZ-01A-21R-A12P-07 | — | A | 0.842 |
| 6 | 87a582d2-22f0-4d22-8d2d-8fec2f1e7e8f | — | — | 0.838 |
| 7 | R314 | — | — | 0.830 |
| 8 | TCGA-BH-A208-01A-11R-A157-07 | — | A | 0.829 |
| 9 | 1b5aacb8-0e2e-4888-bc61-48c4aa4d4684 | — | — | 0.829 |
| 10 | TCGA-DQ-5624-01A-01R-1873-07 | — | — | 0.828 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.380 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.370 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.350 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.310 | Cobimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.310 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.290 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.260 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.240 | Inavolisib | — uncovered |
| COAGULATION | 0.240 | Binimetinib | — uncovered |
| HYPOXIA | 0.240 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.220 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.200 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.180 | Inavolisib | — uncovered |
| COMPLEMENT | 0.170 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.170 | Inavolisib | — uncovered |
| MYOGENESIS | 0.170 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.120 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.120 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.120 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.120 | Inavolisib | — uncovered |